Skip to NavigationSkip to content

Transgene ceases development of failed advanced non-squamous non-small cell lung cancer immunotherapy candidate

Published on 16/12/19 at 03:05pm

Cancer immunotherapeutics firm Transgene has confirmed that it is to terminate further development of its TG4010 candidate in the first-line treatment of advanced non-squamous non-small cell lung cancer (NSCLC) after it was discovered to have failed to meet its primary endpoint at Phase 2.

Specifically, the candidate, when combined with Bristol-Myers Squibb’s Opdivo and chemotherapy, failed to achieve a clinically significant overall response rate in NSCLC patients with low-to-no expression of PD-L1 in their tumours.

The trial was conducted in partnership with BMS and examined the candidate’s efficacy in 40 UK and US patients.

“We are obviously very disappointed with the outcome of this Phase 2 trial which showed that the triple combination regimen of TG4010, chemotherapy and nivolumab did not sufficiently increase the response rate in this patient population with advanced NSCLC whose tumours express low or undetectable levels of PD-L1,” explained Dr Philippe Archinard, Chairman and CEO of Transgene. “Additional data analyses are still ongoing and the complete study results will be presented at an upcoming scientific conference.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches